The global human growth hormone market was valued at $3,864.00 million in 2020 and is expected to reach $9,211.63 million by 2030, registering a CAGR of 9.0% from 2021 to 2030. The human growth hormone also known as somatotropin is a peptide hormone secreted by the pituitary gland that regulates cell growth, cell regeneration & repair, reproduction, and metabolism contributing to the overall development of humans. The growth hormone levels in the human body should be optimum for normal growth and can be regulated by factors such as exercise, sleep, stress, and lower glucose levels. Human growth hormones also help in controlling body composition, muscle & bone growth, body fluids, sugar & fat metabolism, and recovery from injury. It also helps to boost muscle strength & performance. Moreover, lower or higher levels of growth hormone may affect the quality of life thereby, increasing the risks of diseases such as high cholesterol levels, growth hormone deficiency, or poor bone density. Lower levels of human growth hormone increase the risk of diseases and results in fat accumulation throughout the body, whereas higher levels of the same may cause gigantism in children and acromegaly, muscle-wasting disease, and short bowel syndrome in adults. The human growth hormone levels decrease with age. This natural slowdown in the production of growth hormones in human body has triggered the interest in using synthetic growth hormone therapies across the world.
There has been a considerate growth in the human growth hormone market in recent years due to various factors like rise in adaptation of growth hormones for controlling the aging. Growth Hormone treatment is helping in improving the muscle strength body composition, physical function, and bone density. Growth hormones are also helpful in keeping a check over cardio vascular disorders and are used to decrease the levels of cholesterol in the body. Along with this, there has also been a rise in the disorders related to the growth hormones like Prader-Willi Syndrome, small for gestational age (SGA) and Turner Syndrome due to the wide adoption of sedentary lifestyles and increase consumption of alcohol. This surge is anticipated to propel the growth of the market in the near future. Moreover, the rise in the disposable income in the developing economies is expected to create lucrative opportunities in the near future.
Rise in awareness regarding the effectiveness of growth hormones, demand for cost efficient growth hormone therapies; increase in prevalence of serious chronic diseases such as chronic kidney disease and growth retardation, and pituitary dysfunctions; and surge in compliance for growth hormone formulations are the major factors that drive the growth of the global human growth hormone market.
However, the unfavorable effects such as muscle pain, joint pain, and fluid retention associated with the use of synthetic growth hormones and high cost involved in the treatments using these growth hormones hinder the growth of the market. Moreover, stringent government approvals are expected to restrain the growth and development of the market in the coming years. On the contrary, the rise in disposable income and surge in healthcare expenditure in developing economies is anticipated to create lucrative opportunities for the manufactures of growth hormones in the future.
The human growth hormone market is segmented on the basis of application, route of administration, distribution channel, and region. By application, it is categorized into growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, small for gestational age, and others. By route of administration, it is classified into intravenous, intramuscular, subcutaneous, and oral. By distribution channel, it is divided into hospital pharmacy, retail pharmacy, clinic, and online pharmacy. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.
The prominent players in the market have adopted various strategies for increasing their market share. These include expansion of their geographical presence through collaborations and partnerships and increase in investment in developing long-acting and effective products with lower adverse effects. Major players operating in the hGH market include Novo Nordisk, Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Novartis AG, AnkeBio Co. Ltd, F. Hoffmann-La Roche, Ipsen, and Ferring BV.
There has been a considerate growth in the human growth hormone market in recent years due to various factors like rise in adaptation of growth hormones for controlling the aging. Growth Hormone treatment is helping in improving the muscle strength body composition, physical function, and bone density. Growth hormones are also helpful in keeping a check over cardio vascular disorders and are used to decrease the levels of cholesterol in the body. Along with this, there has also been a rise in the disorders related to the growth hormones like Prader-Willi Syndrome, small for gestational age (SGA) and Turner Syndrome due to the wide adoption of sedentary lifestyles and increase consumption of alcohol. This surge is anticipated to propel the growth of the market in the near future. Moreover, the rise in the disposable income in the developing economies is expected to create lucrative opportunities in the near future.
Rise in awareness regarding the effectiveness of growth hormones, demand for cost efficient growth hormone therapies; increase in prevalence of serious chronic diseases such as chronic kidney disease and growth retardation, and pituitary dysfunctions; and surge in compliance for growth hormone formulations are the major factors that drive the growth of the global human growth hormone market.
However, the unfavorable effects such as muscle pain, joint pain, and fluid retention associated with the use of synthetic growth hormones and high cost involved in the treatments using these growth hormones hinder the growth of the market. Moreover, stringent government approvals are expected to restrain the growth and development of the market in the coming years. On the contrary, the rise in disposable income and surge in healthcare expenditure in developing economies is anticipated to create lucrative opportunities for the manufactures of growth hormones in the future.
The human growth hormone market is segmented on the basis of application, route of administration, distribution channel, and region. By application, it is categorized into growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, small for gestational age, and others. By route of administration, it is classified into intravenous, intramuscular, subcutaneous, and oral. By distribution channel, it is divided into hospital pharmacy, retail pharmacy, clinic, and online pharmacy. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.
The prominent players in the market have adopted various strategies for increasing their market share. These include expansion of their geographical presence through collaborations and partnerships and increase in investment in developing long-acting and effective products with lower adverse effects. Major players operating in the hGH market include Novo Nordisk, Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Novartis AG, AnkeBio Co. Ltd, F. Hoffmann-La Roche, Ipsen, and Ferring BV.
KEY BENEFITS FOR STAKEHOLDERS
- The study presents an in-depth analysis of the global human growth hormone market along with the current trends and future estimations from 2021 to 2030 to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, the rise in opportunities, and recognition of the key players that can influence this market on a global & regional scale are provided in the report.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
- The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Application
- Growth hormone deficiency
- Prader-Willi syndrome
- Turner syndrome
- Small for gestational age (SGA)
- Others
By Route of Administration
- Oral
- Intravenous
- Intramuscular
- Subcutaneous
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online Pharmacy
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Novo Nordisk
- Merck & Co.
- Eli Lilly & Company
- Pfizer Inc.
- Teva Pharmaceutical Industries
- Novartis AG
- Anhui Anke Biotechnology (Group) Co., Ltd
- Roche
- Ipsen
- Ferring BV
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
CHAPTER 4: HUMAN GROWTH HORMONE MARKET, BY APPLICATION
CHAPTER 5: HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION
CHAPTER 6: HUMAN GROWTH HORMONE MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: HUMAN GROWTH HORMONE MARKET, BY REGION
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 212 |
| Published | September 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 3864 million |
| Forecasted Market Value ( USD | $ 9211.63 million |
| Compound Annual Growth Rate | 9.1% |
| Regions Covered | Global |
